The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double-Blinded, Randomised, Placebo-Controlled Clinical Trial
Abstract
Irritable bowel syndrome (IBS) is a functional bowel disorder of unknown aetiology. There is currently no known cure, and pharmacological interventions are usually targeting symptomatic relief, where natural and herbal remedies also play a role. This study aimed to evaluate the benefit and tolerability of IQP‐CL‐101 in symptomatic IBS relief. A double‐blinded, randomised, placebo‐controlled trial was conducted over 8 weeks. A total of 99 subjects fulfilling ROME‐III criteria for IBS were randomised into two groups, given either two IQP‐CL‐101 softgels or matching placebo twice daily before main meals. The primary endpoint was the difference in change of IBS Symptom Severity Score (IBS‐SSS) after an 8‐week intake of IQP‐CL‐101 compared to placebo. After 8 weeks, subjects on IQP‐CL‐101 showed a significant reduction in IBS‐SSS (113.0 ± 64.9‐point reduction) compared to subjects on placebo (38.7 ± 64.5‐point reduction) ( p < 0.001). A significant improvement could be seen as early as 4 weeks. No serious adverse events were reported throughout. IQP‐CL‐101 can be considered beneficial in the improvement of IBS symptom severity, regardless of IBS type, and therefore able to improve quality of life in patients suffering from abdominal pain and discomfort. © 2017 The Authors. Phytotherapy Research published by John Wiley & Sons Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It also appears safe and well-tolerated, with no adverse events reported in the available trials.”
From A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS) (2018) · cites this paper as [26]
In the citing paper
“Of the five clinical trials reviewed, three reported positive and significant effects for curcumin-containing products [24,26,28], while two [25,27] found no significant effects compared to placebo and advised against monotherapy with curcumin.”
From A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS) (2018) · cites this paper as [26]
In the citing paper
“Current studies ranged from only 8 to 18 weeks [24,25,26,28].”
From A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS) (2018) · cites this paper as [26]
In the citing paper
“Furthermore, curcumin was mixed with at least one other therapeutic or potentially therapeutic material in two of the trials analysed [26,28], hence, it is difficult to quantify a curcumin-attributable SMD and determine whether the therapeutic benefits observed in these two studies were due to curcumin.”
From A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS) (2018) · cites this paper as [26]
In the citing paper
“Second, inter-study variability in terms of curcumin formulation (even combined with peppermint oil, a known antispasmodic [44], in one study [26]) and the diagnosis of IBS likely contributed to the overall heterogeneity of the meta-analysis, and could have affected the reliability of current findings.”
From A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS) (2018) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
The epidemiology of irritable bowel syndrome
Card, T., Canavan, C., & West, J. (2014) · Clinical Epidemiology · doi:10.2147/clep.s40245 · Cited by 889
Design of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
New insights into the pathogenesis and pathophysiology of irritable bowel syndrome
Öhman, L., & Simrén, M. (2007) · Digestive and Liver Disease · doi:10.1016/j.dld.2006.10.014 · Cited by 155
Research works printed but not linked: 23
- 10.4291/wjgp.v1.i3.97 · DOI
- 10.1136/gut.51.suppl_1.i41 · DOI
- 10.1055/s-0033-1335260 · DOI
- 10.1001/jama.2015.0954 · DOI · Paper page
- Currò D, 2016, Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders, Br J Pharmacol
- ESCOP Monographs, 2003, Carvi fructus—Caraway Fruit
- 10.1016/j.bpg.2004.04.008 · DOI
- 10.1111/j.1365-2036.2010.04328.x · DOI
- Freise J, 1999, Peppermint oil/caraway oil fixed combination in non‐ulcer dyspepsia. Equivalent efficacy of the drug combination in an enteric coated or enteric soluble formulation, Pharmazie, 54, 210
- 10.1016/j.phymed.2004.10.007 · DOI
- 10.1016/j.cgh.2014.03.014 · DOI
- 10.1111/j.1365-2036.2006.02776.x · DOI
- 10.1002/ptr.5591 · DOI · Paper page
- Jurenka J, 2009, Anti‐inflammatory properties of curcumin, a major constituent of Curcuma longa : a review of preclinical and clinical research, Akterbatuve Neducube Rev, 14, 141
- Kunnumakkara AB, 2016, Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases, Br J Pharmacol
- 10.1002/14651858.CD004116.pub2 · DOI
- 10.1111/j.1365-2036.2004.01859.x · DOI · Paper page
- Maroon J, 2006, Fish Oil: The Natural Anti‐inflammatory
- 10.1007/s10620-009-0854-9 · DOI · Paper page
- Schoenfeld PS, 2016, Advances in IBS 2016: a review of current and emerging data, Gastroenterol Hepatol (NY), 12, 1
- 10.1016/j.dld.2009.07.007 · DOI · Paper page
- 10.1038/nrgastro.2016.141 · DOI
- 10.1046/j.1365-2125.2003.01966.x · DOI
Cited by
A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS)
Ng, Q., Soh, A., Loke, W., Venkatanarayanan, N., Lim, D., & Yeo, W.-S. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7100298 · Cited by 95
A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders
Thavorn, K., Wolfe, D., Faust, L., Shorr, R., Akkawi, M., Isaranuwatchai, W., Klinger, C., Chai‐Adisaksopa, C., Tanvejsilp, P., Nochaiwong, S., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8189 · Cited by 11
Metadata
- Authors
- Alt, F., Chong, P., Teng, E., & Uebelhack, R.
- Affiliations
- analyze & realize GmbH Berlin Germany
- Zaluvida Corporate Sdn Bhd Kuala Lumpur Malaysia
- InQpharm Europe Ltd E‐16, Plaza Mont Kiara, 2 Jalan Kiara Kuala Lumpur 50480 Malaysia
- ORCID
- Teng, Emily
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2017-05-16
- Volume
- 31
- Issue
- 7
- Pages
- 1056-1062
- ISSN
- 0951-418X
- 1099-1573
- Cited by
- 24
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double-Blinded, Randomised, Placebo-Controlled Clinical Trial. https://app.cochat.ai/papers/10.1002/ptr.5826
- The paper
- Alt, F., Chong, P., Teng, E., & Uebelhack, R. (2017). Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double-Blinded, Randomised, Placebo-Controlled Clinical Trial. Phytotherapy Research. https://doi.org/10.1002/ptr.5826
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
